Abstract:Background Schizophrenia is a severe psychotic disorder characterized by significant disturbances in thinking, perception, emotions and behavior. Even if it is not a very frequent disorder, but it is the most burdensome and costly illnesses worldwide. The total population was approximate 1.3 billion and there are approximate 8 million schizophrenic patients in China. Despite the wide-ranging financial and social burdens associated with schizophrenia, but there have been few cost-of-illness studies of this illness in China. Objective To evaluate the economic cost of schizophrenic patients in China. Methodology 356 schizophrenic patients who met with DSM-IV criteria were enrolled and investigated with the Economic Burden Questionnaire(EBQ), 299 schizophrenic patients completed the study for 12 months. All the data were combined and classified by researcher. EBQ include all kinds of cost such as direct cost, indirect cost and total cost as well. It was filled in by patients and their close caregivers. Comparison of cost was made between not only out-patients and in-patients but also urban patients and rural patients. Multiple stepwise regression analysis was made to identify the main influence factors of total cost. Results (i) The per case per annum total costs, direct costs and indirect costs of schizophrenia amounted to US$2586.21, US$862.81(33.4%) and US$1723.40(66.6%) respectively. The per case total cost, direct cost and direct medical cost of in-patients were more higher than out-patients ( P < 0.05). (ii) There was significant difference in per case per annum total cost, direct cost, direct medical cost, cost due to lost working-days and disability between urban and rural schizophrenic patients ( P < 0.05), the former is higher than the latter. (iii) The results of multivariate stepwise regression analysis show that five variables were significantly correlated with higher cost: professional status(cadre), diagnostic subtype(residual schizophrenia), urban or rural patients(urban patients), in-patients or out-patients(in-patients) and researcher centre(southern center). The standardized regression coefficient were 0.308, 0.218, 0.212, 0.156 and 0.149 respectively, the correlation of determination R square was 0.2741, F = 15.651, P < 0.0000. These characteristics explain 27.41% of the variability in the total cost. Conclusion (i) Economic cost of schizophrenia were serious, we must pay close attention to it. (ii) The indirect cost are the majority of the total cost. The cost of urban patients are more higher than the cost of rural patients, the cost of in-patients are more higher than the cost of out-patients.

A multicenter study to evaluate the disease burden and health economics of inpatients with multiple sclerosis in China

Healthcare Resource Utilization and Economic Burden of Multiple Sclerosis in Chinese Patients: Results from a Real-World Survey

The burden of multiple sclerosis in China: A literature review

PGI6 DISEASE BURDEN OF MODERATE TO SEVERE CROHN'S DISEASE UNDER CURRENT TREATMENT PATTERN IN CHINA

Prevalence and Burden of Multiple Sclerosis in China, 1990-2019: Findings From the Global Burden of Disease Study 2019

OP115 Effect of Multiple Drug Resistance on Costs for Patients with Intra-Abdominal Infections in China

Global, regional, and national burden of multiple sclerosis from 1990 to 2019: Findings of global burden of disease study 2019

Evaluation of the Disease Burden of Sporadic Creutzfeldt-Jacob Disease with the Surveillance Data from 2013 to 2017 in China

Treatment patterns of patients with multiple sclerosis in China: A single-center experience

Urban Prevalence of Multiple Sclerosis in China: A Population-Based Study in Six Provinces.

Effect of Multiple Drug Resistance on Total Medical Costs among Patients with Intra-Abdominal Infections in China.

Disease Burden of Schizophrenia Patients Visiting a Chinese Regional Mental Health Centre.

Healthcare Cost of Multiple Sclerosis and in Relation to Disability Level in Alberta

PCN15 Disease Burden of Myelodysplastic Syndrome UNDER the Current Treatment Pattern in China

Costs and quality of life in multiple sclerosis

PSS9 Economic Burden of Wet Age-Related Macular Degeneration (WAMD) in Urban China

An Investigation of Economic Costs of Schizophrenia in Two Areas of China

Medical cost and healthcare utilization of amyotrophic lateral sclerosis in China: A cohort study based on hospital data from 2015 to 2018

The cost-of-illness of multiple sclerosis in Jordan

Treatment patterns of patients with multiple sclerosis in Guangzhou, China

PCN161 REAL-WORLD EVIDENCE ON ECONOMIC BURDEN OF MULTIPLE MYELOMA IN CHINA: A RETROSPECTIVE STUDY OF CLAIMS DATA